• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk

BNO Bionomics Receives $7.5M 2014 R&D Tax IncentivePRICE SENSITIVE05/09/14
BNO Bionomics Investor Presentation19/08/14
BNO Full Year Statutory Accounts19/08/14
BNO Bionomics 2013/2014 Preliminary Final ResultsPRICE SENSITIVE19/08/14
BNO Change of Director's Interest Notice13/08/14
BNO Appendix 4C - quarterlyPRICE SENSITIVE31/07/14
BNO Appendix 3B30/06/14
BNO Bionomics and Merck Collaboration Presentation24/06/14
BNO Bionomics and Merck Enter New Research CollaborationPRICE SENSITIVE24/06/14
BNO Trading HaltPRICE SENSITIVE23/06/14
BNOAppendix 3B27/05/14
BNOBNC105 Phase I Ovarian Cancer Trial Update19/05/14
BNOAppendix 4C - quarterlyPRICE SENSITIVE30/04/14
BNOBionomics NOW April 2014 Newsletter17/04/14
BNOBionomics to Feature at US Cancer Conference07/04/14
BNOAppendix 3B28/03/14
BNOBNC105 Results Presentation19/03/14
BNOWebcast - BNC105 Phase II Renal Cancer Trial Results19/03/14
BNOBNC105 Phase II Renal Cancer Trial ResultsPRICE SENSITIVE19/03/14
BNOTrading HaltPRICE SENSITIVE17/03/14
BNOBionomics Wins Awards at Major BioPharma Asia Convention13/03/14
BNOBionomics CEO to Present at Roth Conference10/03/14
AAI +S&P DJ Indices Announces March Quarterly Rebalance07/03/14
BNOBionomics Partner Granted Further $34M in FundingPRICE SENSITIVE24/02/14
BNOHalf Yearly Report and AccountsPRICE SENSITIVE18/02/14
BNOAppendix 3B17/02/14
BNOBNO to Present Melanoma Compound at Lorne Cancer Conference13/02/14
BNOBionomics Investor Presentation03/02/14
BNOBNC105 Achieves High Response Rate in Ovarian CancerPRICE SENSITIVE03/02/14
BNOAppendix 4C - quarterlyPRICE SENSITIVE31/01/14
BNOBNO Showcased at Australasian Neuroscience Meeting29/01/14
BNOUS Cancer Stem Cells Presentation16/01/14
BNOBionomics CEO to Present at Biotech Showcase13/01/14
BNOChange of Director's Interest Notice06/01/14
BNOCleansing Notice Under Section 708A of the Corporations Act06/01/14
BNOAppendix 3B06/01/14
BNOAppendix 3B24/12/13
BNOChange in substantial holding23/12/13
BNOChange of Director's Interest Notice18/12/13
BNOChange of Director's Interest Notice18/12/13
BNOAppendix 3B18/12/13
BNOBionomics Receives $7.04M 2013 R&D Tax IncentivePRICE SENSITIVE18/12/13
BNOAppendix 3B09/12/13
BNOAppendix 3B03/12/13
BNOAnnual General Meeting 2013 Results19/11/13
BNOCEO & Managing Director's AGM Presentation 201319/11/13
BNOChairman's Address to Shareholders19/11/13
BNOBNO Presents Alzheimer's Drug Candidate at US Conferences06/11/13
BNOAppendix 4C - quarterlyPRICE SENSITIVE31/10/13
BNONotice of Annual General Meeting/Proxy Form18/10/13
BNOBionomics Annual Report 201318/10/13
BNOBionomics Presents BNC101 and BNC105 Data in US18/10/13
BNOChange of Director's Interest Notice16/10/13
BNOAppendix 3B16/10/13
BNOChange of Director's Interest Notice10/10/13
BNOAppendix 3B08/10/13
BNOBionomics R&D Tax Incentive For FY2013PRICE SENSITIVE08/10/13
BNOAppendix 3B01/10/13
BNOBionomics to Present BNC375 at COGNITO Neuroscience Meeting27/09/13
BNOChange of Director's Interest Notice24/09/13
BNOAppendix 3B24/09/13
BNOAppendix 3B16/09/13
BNOAppendix 3B06/09/13
BNOChange in substantial holding05/09/13
BNOAppendix 3B26/08/13
BNOAppendix 3B23/08/13
BNOAppendix 3B22/08/13
BNOAppendix 3B15/08/13
BNOFull Year Statutory Accounts15/08/13
BNOBionomics 2012/2013 Preliminary Final ResultsPRICE SENSITIVE15/08/13
BNOChange in substantial holding12/08/13
BNOAppendix 3B07/08/13
BNOBNO Investor Presentation31/07/13
BNOBionomics Signs Option and License Agreement with MerckPRICE SENSITIVE31/07/13
BNOAppendix 4C - quarterlyPRICE SENSITIVE30/07/13
BNOBionomics initiates IND-enabling studies with BNC101PRICE SENSITIVE29/07/13
BNOBNO Cancer Stem Cells Progress Presented at Key Conference25/07/13
BNOAppendix 3B11/07/13
BNOAppendix 3B28/06/13
BNOAppendix 3B18/06/13
BNOChange of Director's Interest Notice18/06/13
BNOBNO completes enrolment in Phase II renal cancer trialPRICE SENSITIVE11/06/13
BNOAppendix 3B07/06/13
BNOBNC105 Trials Presented at ASCOPRICE SENSITIVE03/06/13
BNOCTX AND BIONOMICS' PROGRAM REACHES KEY MILESTONEPRICE SENSITIVE16/05/13
BNOChange of Director's Interest Notice07/05/13
BNOBionomics NOW May 2013 Newsletter06/05/13
BNOAppendix 3B02/05/13
BNOAppendix 4C - quarterlyPRICE SENSITIVE30/04/13
BNOUpdate on BNC101 Presented at Leading US Antibody Conference29/04/13
BNOManufacture of BNC101 commences at LonzaPRICE SENSITIVE23/04/13
BNORights Issue - Despatch of Holding Statements16/04/13
BNOChange of Director's Interest Notice15/04/13
BNOChange of Director's Interest Notice15/04/13
BNOChange of Director's Interest Notice15/04/13
BNONon-renounceable rights issue - Share allotment11/04/13
BNORights Issue Closure and Shortfall Notice08/04/13
BNOAppendix 3B25/03/13
BNORights Issue - Despatch of Offer Booklet18/03/13
BNORights Issue - Letter to Ineligible Shareholders18/03/13
BNO Bionomics Receives $7.5M 2014 R&D Tax Incentive
05/09/14PRICE SENSITIVE
BNO Bionomics Investor Presentation
19/08/14
BNO Full Year Statutory Accounts
19/08/14
BNO Bionomics 2013/2014 Preliminary Final Results
19/08/14PRICE SENSITIVE
BNO Change of Director's Interest Notice
13/08/14
BNO Appendix 4C - quarterly
31/07/14PRICE SENSITIVE
BNO Appendix 3B
30/06/14
BNO Bionomics and Merck Collaboration Presentation
24/06/14
BNO Bionomics and Merck Enter New Research Collaboration
24/06/14PRICE SENSITIVE
BNO Trading Halt
23/06/14PRICE SENSITIVE
BNOAppendix 3B
27/05/14
BNOBNC105 Phase I Ovarian Cancer Trial Update
19/05/14
BNOAppendix 4C - quarterly
30/04/14PRICE SENSITIVE
BNOBionomics NOW April 2014 Newsletter
17/04/14
BNOBionomics to Feature at US Cancer Conference
07/04/14
BNOAppendix 3B
28/03/14
BNOBNC105 Results Presentation
19/03/14
BNOWebcast - BNC105 Phase II Renal Cancer Trial Results
19/03/14
BNOBNC105 Phase II Renal Cancer Trial Results
19/03/14PRICE SENSITIVE
BNOTrading Halt
17/03/14PRICE SENSITIVE
BNOBionomics Wins Awards at Major BioPharma Asia Convention
13/03/14
BNOBionomics CEO to Present at Roth Conference
10/03/14
AAI +S&P DJ Indices Announces March Quarterly Rebalance
07/03/14
BNOBionomics Partner Granted Further $34M in Funding
24/02/14PRICE SENSITIVE
BNOHalf Yearly Report and Accounts
18/02/14PRICE SENSITIVE
BNOAppendix 3B
17/02/14
BNOBNO to Present Melanoma Compound at Lorne Cancer Conference
13/02/14
BNOBionomics Investor Presentation
03/02/14
BNOBNC105 Achieves High Response Rate in Ovarian Cancer
03/02/14PRICE SENSITIVE
BNOAppendix 4C - quarterly
31/01/14PRICE SENSITIVE
BNOBNO Showcased at Australasian Neuroscience Meeting
29/01/14
BNOUS Cancer Stem Cells Presentation
16/01/14
BNOBionomics CEO to Present at Biotech Showcase
13/01/14
BNOChange of Director's Interest Notice
06/01/14
BNOCleansing Notice Under Section 708A of the Corporations Act
06/01/14
BNOAppendix 3B
06/01/14
BNOAppendix 3B
24/12/13
BNOChange in substantial holding
23/12/13
BNOChange of Director's Interest Notice
18/12/13
BNOChange of Director's Interest Notice
18/12/13
BNOAppendix 3B
18/12/13
BNOBionomics Receives $7.04M 2013 R&D Tax Incentive
18/12/13PRICE SENSITIVE
BNOAppendix 3B
09/12/13
BNOAppendix 3B
03/12/13
BNOAnnual General Meeting 2013 Results
19/11/13
BNOCEO & Managing Director's AGM Presentation 2013
19/11/13
BNOChairman's Address to Shareholders
19/11/13
BNOBNO Presents Alzheimer's Drug Candidate at US Conferences
06/11/13
BNOAppendix 4C - quarterly
31/10/13PRICE SENSITIVE
BNONotice of Annual General Meeting/Proxy Form
18/10/13
BNOBionomics Annual Report 2013
18/10/13
BNOBionomics Presents BNC101 and BNC105 Data in US
18/10/13
BNOChange of Director's Interest Notice
16/10/13
BNOAppendix 3B
16/10/13
BNOChange of Director's Interest Notice
10/10/13
BNOAppendix 3B
08/10/13
BNOBionomics R&D Tax Incentive For FY2013
08/10/13PRICE SENSITIVE
BNOAppendix 3B
01/10/13
BNOBionomics to Present BNC375 at COGNITO Neuroscience Meeting
27/09/13
BNOChange of Director's Interest Notice
24/09/13
BNOAppendix 3B
24/09/13
BNOAppendix 3B
16/09/13
BNOAppendix 3B
06/09/13
BNOChange in substantial holding
05/09/13
BNOAppendix 3B
26/08/13
BNOAppendix 3B
23/08/13
BNOAppendix 3B
22/08/13
BNOAppendix 3B
15/08/13
BNOFull Year Statutory Accounts
15/08/13
BNOBionomics 2012/2013 Preliminary Final Results
15/08/13PRICE SENSITIVE
BNOChange in substantial holding
12/08/13
BNOAppendix 3B
07/08/13
BNOBNO Investor Presentation
31/07/13
BNOBionomics Signs Option and License Agreement with Merck
31/07/13PRICE SENSITIVE
BNOAppendix 4C - quarterly
30/07/13PRICE SENSITIVE
BNOBionomics initiates IND-enabling studies with BNC101
29/07/13PRICE SENSITIVE
BNOBNO Cancer Stem Cells Progress Presented at Key Conference
25/07/13
BNOAppendix 3B
11/07/13
BNOAppendix 3B
28/06/13
BNOAppendix 3B
18/06/13
BNOChange of Director's Interest Notice
18/06/13
BNOBNO completes enrolment in Phase II renal cancer trial
11/06/13PRICE SENSITIVE
BNOAppendix 3B
07/06/13
BNOBNC105 Trials Presented at ASCO
03/06/13PRICE SENSITIVE
BNOCTX AND BIONOMICS' PROGRAM REACHES KEY MILESTONE
16/05/13PRICE SENSITIVE
BNOChange of Director's Interest Notice
07/05/13
BNOBionomics NOW May 2013 Newsletter
06/05/13
BNOAppendix 3B
02/05/13
BNOAppendix 4C - quarterly
30/04/13PRICE SENSITIVE
BNOUpdate on BNC101 Presented at Leading US Antibody Conference
29/04/13
BNOManufacture of BNC101 commences at Lonza
23/04/13PRICE SENSITIVE
BNORights Issue - Despatch of Holding Statements
16/04/13
BNOChange of Director's Interest Notice
15/04/13
BNOChange of Director's Interest Notice
15/04/13
BNOChange of Director's Interest Notice
15/04/13
BNONon-renounceable rights issue - Share allotment
11/04/13
BNORights Issue Closure and Shortfall Notice
08/04/13
BNOAppendix 3B
25/03/13
BNORights Issue - Despatch of Offer Booklet
18/03/13
BNORights Issue - Letter to Ineligible Shareholders
18/03/13
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.